文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

新型运动恢复模式反映心脏性能:SEQUOIA-HCM试验子研究

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
PubMed 文献 · Circulation · 2025-09-05

研究在814例劳力性呼吸困难患者中评估运动后摄氧恢复(VO2Rec)模式,发现VO2T12.5%延长与运动肺毛细血管楔压/心输出量斜率升高相关,且每延长15秒心衰住院或全因死亡风险增加54%。在SEQUOIA-HCM试验中,aficamten治疗24周使VO2T12.5%较安慰剂改善8秒,且改善与NT-proBNP、hs-cTnI及左室流出道梯度降低相关。

要点

  • VO2T12.5%是反映运动心脏性能的新指标,可预测心衰住院和死亡。
  • VO2T12.5%每延长15秒,心衰住院或全因死亡风险增加54%。
  • aficamten治疗24周使VO2T12.5%改善8秒,且与心脏生物标志物和流出道梯度改善相关。

核心结论

  • VO2T12.5%是反映运动心脏性能的新指标,可预测心衰事件无生存。
  • aficamten治疗可改善VO2T12.5%,且与左室流出道梯度和心脏生物标志物改善成比例。

研究设计与样本

  • 研究包括MGH-ExS转诊队列(814例劳力性呼吸困难患者,58±16岁,58%女性)和SEQUOIA-HCM随机对照试验(aficamten vs 安慰剂24周,n=263,59.1±2.9岁,41%女性)。
  • VO2Rec统一测量为VO2从峰值下降>0%、12.5%(VO2T12.5%)、25%和50%所需时间。

主要发现

  • MGH-ExS队列中,VO2T12.5%≥35秒者运动肺毛细血管楔压/心输出量斜率升高(P<0.0001),外周氧摄取无差异(P=0.11)。
  • VO2T12.5%每增加15秒,心衰住院和全因死亡的风险比为1.54(95%CI 1.35-1.76;P<0.001)。
  • SEQUOIA-HCM中,基线VO2T12.5%为45±20秒,aficamten组较安慰剂组改善8秒(95%CI -12至-5秒;P<0.001)。
  • aficamten组VO2T12.5%改善≥15秒的比值比为3.7(95%CI 1.9-6.9),需治疗人数为4.8。
  • VO2T12.5%缩短与NT-proBNP、高敏肌钙蛋白I和左室流出道梯度降低相关(均P<0.005)。

临床怎么用

  • VO2T12.5%简单且生理相关,支持常规纳入心肺运动试验方案以评估运动中心脏功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-exercise oxygen uptake recovery (VO2Rec) is slow in advanced heart failure. We sought to establish easily derived VO2Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VO2Rec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy. METHODS: VO2Rec patterns were evaluated in relation to cardiac performance and the primary outcome of heart failure hospitalization or death in a referral cohort with dyspnea on exertion undergoing cardiopulmonary exercise testing with hemodynamic monitoring (MGH-ExS [Massachusetts General Hospital Exercise Study]). We then investigated longitudinal measures of VO2Rec in the pivotal phase 3 randomized controlled trial SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in Hypertrophic Cardiomyopathy) of aficamten versus placebo for 24 weeks in participants with symptomatic obstructive hypertrophic cardiomyopathy. For both cohorts, VO2Rec was uniformly measured as time for VO2 to decline by >0%, 12.5% (VO2T12.5%), 25%, and 50% of peak VO2. RESULTS: Among 814 MGH-ExS patients (58±16 years of age, 58% women), those with a longer VO2T12.5% (≥35 versus <35 seconds) demonstrated elevated exercise pulmonary capillary wedge pressure to cardiac output slope (P<0.0001) with no difference in peripheral oxygen extraction (P=0.11). For each 15-second increase in VO2T12.5%, the hazard ratio for heart failure hospitalization and all-cause death was 1.54 (95% CI, 1.35-1.76; P<0.001). In SEQUOIA-HCM participants with cardiopulmonary exercise testing at baseline and week 24 (n=263, 59.1±2.9 years of age, 41% women), baseline VO2T12.5% was 45±20 seconds and improved 8 seconds (95% CI, -12 to -5 seconds; P<0.001) with aficamten treatment compared with placebo at 24 weeks. Participants treated with aficamten versus placebo were more likely to improve VO2T12.5% by ≥15 seconds (odds ratio [OR], 3.7 [95% CI, 1.9-6.9]; number needed to treat=4.8). Shortening of VO2T12.5% correlated with reduced NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin I, and left ventricular outflow tract gradient (all P<0.005). CONCLUSIONS: This study established VO2T12.5% as a new measure that reflects cardiac performance during exercise and predicted heart failure event-free survival. Furthermore, VO2T12.5% improved proportional to improvements in left ventricular outflow tract gradient and cardiac biomarkers in response to aficamten treatment, a cardiospecific therapy for obstructive hypertrophic cardiomyopathy. The simplicity and physiological relevance of VO2T12.5% support its regular inclusion in cardiopulmonary exercise testing protocols evaluating cardiac function during exercise. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05186818.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Campain J, Griskowitz C, Newlands C, et al. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. Circulation. 2025. PMID: 40910168. doi:10.1161/CIRCULATIONAHA.124.073585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。